ReviewNature reviews. Neurology2011
Monoclonal antibody therapy-associated neurological disorders.
Review in Nature reviews. Neurology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 133 citations in OpenAlex.
- Review
- Infliximab-associated multifocal central nervous system demyelination mimicking multiple sclerosis in a patient with Crohn's disease: a case report.BMC neurology · 2026Article
- Article
- Article
- Tumefactive Demyelinating Lesion Induced by Infliximab in a Patient With Rheumatoid Arthritis: A Case Report.Clinical case reports · 2025Article
- Treatment Options for the Comorbidity of Multiple Sclerosis with Other Chronic Inflammatory Diseases.Deutsches Arzteblatt international · 2025Review
- Severe bilateral chorioretinopathy associated with ipilimumab in a patient with metastatic melanoma.GMS ophthalmology cases · 2025Article
- The contribution of tumor necrosis factor to multiple sclerosis: a possible role in progression independent of relapse?Journal of neuroinflammation · 2024Review
- Demyelinating plaque-associated uveitis.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2024Observational
- Monoclonal Antibodies: What the Diagnostic Neuroradiologist Needs to Know.AJNR. American journal of neuroradiology · 2023Review
- Genetics of circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targets.Nature immunology · 2023Article
- Role of tumor necrosis factor-alpha in the central nervous system: a focus on autoimmune disorders.Frontiers in immunology · 2023Review
- Adverse drug reactions of Rituximab in patients suffering from autoimmune neurological diseases.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2022Observational
- Paradoxical Reactions to Biologicals in Chronic Inflammatory Systemic Diseases.Deutsches Arzteblatt international · 2022Article
- Genetics and functional genomics of multiple sclerosis.Seminars in immunopathology · 2022Review
- The causal relationship between neuromyelitis optica spectrum disorder and other autoimmune diseases.Frontiers in immunology · 2022Article
- Drug-related immune-mediated myelopathies.Frontiers in neurology · 2022Review
- Demyelinating disease (multiple sclerosis) in a patient with psoriatic arthritis treated with adalimumab: a case-based review.Rheumatology international · 2021Review
- Clinical course of central nervous system demyelinating neurological adverse events associated with anti-TNF therapy.Journal of neurology · 2021Article
- Biologic Therapies and Autoimmune Phenomena.Mediterranean journal of rheumatology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several neurological disorders have been associated with the use of monoclonal antibodies (mAbs), especially those targeting tumor necrosis factor (TNF) and its receptors. These disorders include, among others, multiple sclerosis, optic neuritis, and various forms of peripheral demyelinating neuropathy. Progressive multifocal leukoencephalopathy, the natural course of which is lethal within months, has been mainly associated with the anti-α4-integrin mAb natalizumab and, to a lesser extent, with rituximab, alemtuzumab and efalizumab. The prevalence of demyelinating disease induced by biological therapies, as reported in randomized controlled trials and postmarketing studies, has been estimated to range from 0.02-0.20%. Peripheral neuropathies can occur early or late after initiation of therapy. Short-term follow-up indicates relatively good outcomes, sometimes after mAb discontinuation alone, although corticosteroids or intravenous immunoglobulin may be necessary to reverse and stabilize the condition. Definitive cessation of the biological therapy should be discussed on a case-by-case basis. Prospective postmarketing studies in which the control group includes patients with rheumatic autoimmune diseases-most notably rheumatoid arthritis-treated with conventional therapies could help us to evaluate the real risks and outcomes in patients receiving mAbs who develop neurological diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.